NCT06698159 Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The WIDER PVI study is a multicentre randomized clinical trial to compare the efficacy of antral versus extended antral PVI in patients with paroxysmal or persistent AF undergoing this procedure using a cryoablation balloon capable of 28 mm diameter (antral isolation) or 31 mm diameter (extended antral isolation) applications. The aim is to evaluate an objective of superiority of the extended antral isolation strategy versus antral isolation in the recurrence of atrial tachyarrhythmias at 1-year follow-up, both in episodes of \>30 seconds duration and in overall arrhythmic load.

Eligibility Criteria

Inclusion Criteria: * Age over 18 years old. * Previous diagnosis of paroxysmal or persistent atrial fibrillation less than 2 years after diagnosis. * Clinical indication to undergo a pulmonary vein isolation procedure using balloon cryoablation. Exclusion Criteria: * Severe left atrial dilatation (indexed volume \>48 ml/m2 or area \>40 cm2 or indexed diameter \>3.0 cm/m2). * Previous endocardial or surgical ablation of atrial fibrillation. * Severe frailty (Clinical Frailty Scale score 7 or higher) or life expectancy less than 1 year. * Inability to understand or give informed consent. * Performance of other left atrial ablations in addition to pulmonary veins. * Need to use another catheter in addition to the cryoablation catheter to complete pulmonary vein isolation. * Contraindication to anticoagulation or intolerance to heparin. * Presence of intra-atrial thrombus. * Reversible cause of atrial fibrillation. * Severe mitral or aortic valve disease. * Congenital heart disease. * Pre

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.